DEPIST-FMF: A Diagnostic Test for Familial Mediterranean Fever

Sponsor
Hospices Civils de Lyon (Other)
Overall Status
Completed
CT.gov ID
NCT03747315
Collaborator
(none)
107
4
24
26.8
1.1

Study Details

Study Description

Brief Summary

Familial Mediterranean Fever (FMF) is the most common auto-inflammatory disease (prevalence:

1-5 / 10,000 inhabitants). It is due to mutations of the MEFV gene, encoding variants of the Pyrin inflammasome. Inflammasomes are protein complexes of innate immunity producing pro-inflammatory cytokines (interleukin-1β).

In vitro, preliminary results demonstrated that activation of the Pyrin inflammasome (measured by interleukin-1β concentration) by kinase inhibitors is significantly increased in FMF patients compared to subjects with a similar clinical picture, and healthy controls. In addition, a measure of cell death yielded significant results in differentiating patients from controls.

The investigators hypothesize that this fast and simple functional test can serve as a diagnostic tool for FMF.

Condition or Disease Intervention/Treatment Phase
  • Other: In vitro functional test
  • Other: In vitro functional test

Study Design

Study Type:
Observational
Actual Enrollment :
107 participants
Observational Model:
Case-Control
Time Perspective:
Prospective
Official Title:
Assessment of a Functional Test to Detect Familial Mediterranean Fever
Actual Study Start Date :
Dec 15, 2018
Actual Primary Completion Date :
Dec 15, 2020
Actual Study Completion Date :
Dec 15, 2020

Arms and Interventions

Arm Intervention/Treatment
Familial Mediterranean Fever (patients)

Patients with previously confirmed Familial Mediterranean Fever (based on clinical criteria)

Other: In vitro functional test
Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.

Control group (patients)

Patients with symptoms similar to that of Familial Mediterranean Fever (e.g. Behcet disease, Crohn, sepsis..) but without confirmed Familial Mediterranean Fever.

Other: In vitro functional test
Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on an additional blood sample (4 ml for children under 12 and 10 ml for children 12 years and older and adults) during a sample for patient care.

Healthy donors

Patients without symptoms (anonymous blood donors)

Other: In vitro functional test
Measurement of interleukin-1beta secretion by monocytes and measurement of cell death upon Pyrin inflammasome activation by kinase inhibitor on samples from healthy subjects who donated their blood to the French Blood Establishment.

Outcome Measures

Primary Outcome Measures

  1. Differences in interleukin-1bβ levels [Less than 48 hours]

    Quantification of the capacity of interleukin-1β concentration measured in primary monocyte supernatants in response to kinase inhibitors, to discriminate Familial Mediterranean Fever subjects from control subjects (healthy subjects and subjects with symptoms similar to those of Familial Mediterranean Fever). Analysis have to be performed Less than 48 hours after blood sampling (only one sampling).

Eligibility Criteria

Criteria

Ages Eligible for Study:
4 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • Clinical picture compatible with an Familial Mediterranean Fever and an earlier genetic analysis finding a mutation of the MEFV gene;

  • Newly diagnosed or undergoing follow-up (without criteria of delay or evolutionary stage);

  • In the course of specific or non-specific treatment of the disease or without treatment;

  • For whom a blood test is planned as part of the routine care;

  • Of whom the informed non-opposition has been collected (parental authorization in the case of a minor patient);

Exclusion Criteria:
  • patient under legal protection or under safeguard of justice or any other measures of protection (guardianship, curatorship);

  • Person unable to express his consent;

  • Person in emergency situation, vital or not;

  • Infection known to HIV and / or HBV and / or HCV

Contacts and Locations

Locations

Site City State Country Postal Code
1 Service de néphrologie et rhumatologie pédiatrique, Hôpital Femme Mère Enfant Bron France 69500
2 Unité Inserm U1111 & Service de Médecine Interne, Hôpital de la Croix-Rousse Lyon France 69004
3 Service de Médecine Interne, Pavillon O - Hopital Edouard Herriot Lyon France 69437
4 Service de Médecine Interne et pathologies vasculaires, Batiment 1B, Centre Hospitalier Lyon Sud Pierre-Bénite France 69495

Sponsors and Collaborators

  • Hospices Civils de Lyon

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Hospices Civils de Lyon
ClinicalTrials.gov Identifier:
NCT03747315
Other Study ID Numbers:
  • 69HCL17_0710
First Posted:
Nov 20, 2018
Last Update Posted:
Jun 8, 2021
Last Verified:
Jun 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jun 8, 2021